CLINICAL RESEARCH: CORONARY ARTERY DISEASE
Serum Concentrations of Adiponectin and Risk of Type 2 Diabetes Mellitus and Coronary Heart Disease in Apparently Healthy Middle-Aged Men
Results From the 18-Year Follow-Up of a Large Cohort From Southern Germany
Wolfgang Koenig, MD, FACC*,*,
Natalie Khuseyinova, MD*,
Jens Baumert, PhD ,
Christa Meisinger, MD, MPH, and
Hannelore Löwel, MD
* Department of Internal Medicine II—Cardiology, University of Ulm Medical Center, Ulm, Germany
GSF - National Research Center for Environment and Health, Institute of Epidemiology, Neuherberg, Germany
MONICA/KORA Myocardial Infarction Registry, Augsburg Central Hospital, Augsburg, Germany.
Manuscript received April 6, 2006;
revised manuscript received June 7, 2006,
accepted June 12, 2006.
* Reprint requests and correspondence: Dr. Wolfgang Koenig, Department of Internal Medicine II—Cardiology, University of Ulm Medical Center, Robert-Koch Str. 8, D – 89081 Ulm, Germany. (Email: wolfgang.koenig{at}uniklinik-ulm.de).
OBJECTIVES: We sought to assess the association between serum concentrations of adiponectin and long-term risk of type 2 diabetes mellitus (T2DM) and coronary heart disease (CHD) in initially healthy middle-aged men within the same representative population in Augsburg, southern Germany.
BACKGROUND: It has been postulated that high serum concentrations of adiponectin, an emerging biomarker that is linked to insulin resistance and endothelial dysfunction, may be protective against T2DM and CHD.
METHODS: Serum concentrations of adiponectin were determined in apparently healthy middle-aged men, sampled from the general population in 1984/1985 and followed until 2002. During this period, 115 of 887 men had a newly diagnosed T2DM, and 126 of 937 men suffered from a CHD event.
RESULTS: In a Cox model, after multivariable adjustment for cardiovascular risk factors, the hazard ratio of incident T2DM, comparing extreme tertiles of the adiponectin distribution, was 0.55 (95% confidence interval [CI], 0.35 to 0.89), and for incident CHD it was 0.62 (95% CI, 0.39 to 0.98). Further adjustment for high-density lipoprotein cholesterol (HDL-C) attenuated the association, which became formally non-significant. In joint analysis, men with low adiponectin and low HDL-C values showed a 2.63 times (95% CI, 1.66 to 4.15) increased incidence of T2DM and a 1.91 times (95% CI, 1.20 to 3.04) increased incidence of CHD after multivariable adjustment in comparison with men with high HDL-C and high adiponectin.
CONCLUSIONS: For patients with low HDL-C values, additional measurement of adiponectin may be helpful to identify individuals at very high risk for T2DM and CHD.
|
Abbreviations and Acronyms
| | AMI = acute myocardial infarction | | Apo = apolipoprotein | | ARIC = Atherosclerosis Risk In Communities Study | | BMI = body mass index | | CHD = coronary heart disease | | CI = confidence interval | | CRP = C-reactive protein | | CV = coefficient of variation | | ELISA = enzyme-linked immunosorbent assay | | HDL-C = high-density lipoprotein cholesterol | | HPFU = Health Professionals’ Follow-Up study | | HR = hazard ratio | | KORA = KOoperative Gesundheitsforschung in der Region Augsburg | | LPL = lipoprotein lipase | | Lp-PLA2 = lipoprotein-associated phospholipase A2 | | MI = myocardial infarction | | MONICA = MONItoring of trends and determinants in CArdiovascular disease | | RR = relative risk | | SMC = smooth muscle cell | | TC = total cholesterol | | T2DM = type 2 diabetes mellitus |
|
This article has been cited by other articles:
|
|
|
|
 
J. Paulo Araujo, P. Lourenco, F. Rocha-Goncalves, A. Ferreira, and P. Bettencourt
Adiponectin is increased in cardiac cachexia irrespective of body mass index
Eur J Heart Fail,
June 1, 2009;
11(6):
567 - 572.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Erbel, J. A.C. Delaney, N. Lehmann, R. L. McClelland, S. Mohlenkamp, R. A. Kronmal, A. Schmermund, S. Moebus, N. Dragano, A. Stang, et al.
Signs of subclinical coronary atherosclerosis in relation to risk factor distribution in the Multi-Ethnic Study of Atherosclerosis (MESA) and the Heinz Nixdorf Recall Study (HNR)
Eur. Heart J.,
November 2, 2008;
29(22):
2782 - 2791.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Heidemann, Q. Sun, R. M. van Dam, J. B. Meigs, C. Zhang, S. S. Tworoger, C. S. Mantzoros, and F. B. Hu
Total and High-Molecular-Weight Adiponectin and Resistin in Relation to the Risk for Type 2 Diabetes in Women
Ann Intern Med,
September 2, 2008;
149(5):
307 - 316.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. Maiolino, M. Cesari, D. Sticchi, M. Zanchetta, L. Pedon, K. Antezza, A. C. Pessina, and G. P. Rossi
Plasma Adiponectin for Prediction of Cardiovascular Events and Mortality in High-Risk Patients
J. Clin. Endocrinol. Metab.,
September 1, 2008;
93(9):
3333 - 3340.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. von Eynatten, A. Hamann, D. Twardella, P. P. Nawroth, H. Brenner, and D. Rothenbacher
Atherogenic dyslipidaemia but not total- and high-molecular weight adiponectin are associated with the prognostic outcome in patients with coronary heart disease
Eur. Heart J.,
May 2, 2008;
29(10):
1307 - 1315.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J.-P. Empana
Adiponectin isoforms and cardiovascular disease: the epidemiological evidence has just begun
Eur. Heart J.,
May 2, 2008;
29(10):
1221 - 1223.
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. I. Yilmaz, M. Saglam, A. R. Qureshi, J. J. Carrero, K. Caglar, T. Eyileten, A. Sonmez, E. Cakir, Y. Oguz, A. Vural, et al.
Endothelial dysfunction in type-2 diabetics with early diabetic nephropathy is associated with low circulating adiponectin
Nephrol. Dial. Transplant.,
May 1, 2008;
23(5):
1621 - 1627.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. D. Abel, S. E. Litwin, and G. Sweeney
Cardiac Remodeling in Obesity
Physiol Rev,
April 1, 2008;
88(2):
389 - 419.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. M. Dekker, T. Funahashi, G. Nijpels, S. Pilz, C. D. A. Stehouwer, M. B. Snijder, L. M. Bouter, Y. Matsuzawa, I. Shimomura, and R. J. Heine
Prognostic Value of Adiponectin for Cardiovascular Disease and Mortality
J. Clin. Endocrinol. Metab.,
April 1, 2008;
93(4):
1489 - 1496.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Schnabel, C. M. Messow, E. Lubos, C. Espinola-Klein, H. J. Rupprecht, C. Bickel, C. Sinning, S. Tzikas, T. Keller, S. Genth-Zotz, et al.
Association of adiponectin with adverse outcome in coronary artery disease patients: results from the AtheroGene study
Eur. Heart J.,
March 1, 2008;
29(5):
649 - 657.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. Nagel, K. Rapp, M. Wabitsch, G. Buchele, A. Kroke, I. Zollner, S. K. Weiland, and W. Koenig
Prevalence and Cluster of Cardiometabolic Biomarkers in Overweight and Obese Schoolchildren: Results from a Large Survey in Southwest Germany
Clin. Chem.,
February 1, 2008;
54(2):
317 - 325.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. R. S. Packard and P. Libby
Inflammation in Atherosclerosis: From Vascular Biology to Biomarker Discovery and Risk Prediction
Clin. Chem.,
January 1, 2008;
54(1):
24 - 38.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. G. Wannamethee, G. D.O. Lowe, A. Rumley, L. Cherry, P. H. Whincup, and N. Sattar
Adipokines and Risk of Type 2 Diabetes in Older Men
Diabetes Care,
May 1, 2007;
30(5):
1200 - 1205.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. N. DeMaria, O. Ben-Yehuda, G. K. Feld, G. S. Ginsburg, B. H. Greenberg, W. Y.W. Lew, J. A.C. Lima, A. S. Maisel, J. Narula, D. J. Sahn, et al.
Highlights of the Year in JACC 2006
J. Am. Coll. Cardiol.,
January 30, 2007;
49(4):
509 - 527.
[Full Text]
[PDF]
|
|
|
|
